Hangzhou Tigermed Consulting Co. Ltd
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and to… Read more
Hangzhou Tigermed Consulting Co. Ltd (HNGZY) - Total Liabilities
Latest total liabilities as of September 2025: $4.08 Billion USD
Based on the latest financial reports, Hangzhou Tigermed Consulting Co. Ltd (HNGZY) has total liabilities worth $4.08 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hangzhou Tigermed Consulting Co. Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Hangzhou Tigermed Consulting Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hangzhou Tigermed Consulting Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Hangzhou Tigermed Consulting Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wanxiang Qianchao Co Ltd
SHE:000559
|
China | CN¥15.04 Billion |
|
Provident Financial Services Inc
NYSE:PFS
|
USA | $22.15 Billion |
|
ENN Ecological Holdings Co Ltd
SHG:600803
|
China | CN¥74.94 Billion |
|
Tomra Systems ASA
PINK:TMRAF
|
USA | $1.16 Billion |
|
China Nuclear Engineering Co
SHG:601611
|
China | CN¥210.05 Billion |
|
Haemonetics Corporation
NYSE:HAE
|
USA | $1.58 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Hangzhou Tigermed Consulting Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou Tigermed Consulting Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou Tigermed Consulting Co. Ltd (2009–2024)
The table below shows the annual total liabilities of Hangzhou Tigermed Consulting Co. Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.61 Billion | -11.87% |
| 2023-12-31 | $5.23 Billion | +9.69% |
| 2022-12-31 | $4.77 Billion | +51.96% |
| 2021-12-31 | $3.14 Billion | +90.34% |
| 2020-12-31 | $1.65 Billion | -18.07% |
| 2019-12-31 | $2.01 Billion | +61.44% |
| 2018-12-31 | $1.25 Billion | +63.00% |
| 2017-12-31 | $764.18 Million | +39.31% |
| 2016-12-31 | $548.54 Million | +0.81% |
| 2015-12-31 | $544.12 Million | +23.46% |
| 2014-12-31 | $440.72 Million | +733.66% |
| 2013-12-31 | $52.87 Million | +37.24% |
| 2012-12-31 | $38.52 Million | -5.43% |
| 2011-12-31 | $40.73 Million | +68.85% |
| 2010-12-31 | $24.12 Million | +4.29% |
| 2009-12-31 | $23.13 Million | -- |